Washington, DC - Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Eli Lilly and Company’s acquisition of Novartis Animal Health would likely be anticompetitive.

Under the order, first announced in December 2014, Eli Lilly and Company has agreed to divest its Sentinel product line of medications for treating heartworm disease in dogs, and associated assets, to the French pharmaceutical company, Virbac S.A.

The Commission vote approving the final order was 5-0. (FTC File No. 141 0142; the staff contact is Michael Barnett, Bureau of Competition, 202-326-2362)